Occupational medical standards for the fire service do not publish a blanket prohibited medication list that bans testosterone replacement therapy (TRT), nor do routine department evaluations include endocrine hormone assays. Instead, occupational medical programs function through mandatory self-reporting of prescription drugs and clinician reviews of underlying health conditions.
The Verdict
Consolidation of NFPA 1582 into the NFPA 1580 Standard
The standalone occupational medical standard known as NFPA 1582 no longer exists in an independent format, having been integrated into the consolidated NFPA 1580 standard. The National Fire Protection Association (NFPA) assembled NFPA 1580, titled Standard for Emergency Responder Occupational Health and Wellness, by combining four previously distinct documents: NFPA 1581 for infection control, NFPA 1582 for occupational medical programs, NFPA 1583 for health-related fitness programs, and NFPA 1584 for emergency operation rehabilitation.
The current edition of NFPA 1580 was published in 2025. The final standalone release of NFPA 1582 was the 2022 edition, which outlined an occupational medical program designed to reduce health risks and ensure the operational effectiveness of members operating to protect life and property.
Local fire departments adopt these standards with time lags rather than immediate synchronisation. In a fatality report designated F2025-04, the National Institute for Occupational Safety and Health (NIOSH) documented a career department whose governing policy, dated October 2016, formally adopted the 2013 edition of NFPA 1582 by reference with specific chapters excepted. When evaluating how medical standards govern therapy, members must identify which historical edition of the standard their municipal authority actually enforces.
Duty-to-Report Requirements and Department Medical Evaluations
Fire department occupational physicals screen operational capacity and organ function without measuring circulating serum testosterone levels. A standard pre-placement or periodic evaluation documented by NIOSH includes urinalysis, a vision test, a hearing exam, a chest x-ray, blood work, a pulmonary function test, an electrocardiogram (EKG), a urine or breath alcohol and drug screen, an examination of organ systems, and a respirator fit test. No hormone, endocrine, or testosterone assay appears on that screening panel.
Across the entire 21-page NIOSH report evaluating the medical policies, physical records, autopsy findings, and toxicology results of case F2025-04, words like testosterone, hormone, endocrine, and steroid appeared zero times. Instead of laboratory detection, medications enter the occupational record through administrative disclosure rules. Department policies require members to immediately report any medical condition or use of prescription or non-prescription drugs to the fire department physician if it could interfere with essential job performance.
Relying on the member to declare rather than on an assay to detect is not unique to the fire service. Commercial drivers are screened on a federal drug panel barred from testing for anabolic steroids, so a testosterone prescription ordinarily reaches the record because the driver declares it rather than because the panel found it. Pilots are the exception in the group: the FAA's CACI pathway asks for the laboratory documentation up front and issues on the spot when it satisfies the worksheet.
The standard defines the fire department physician as a licensed medical practitioner designated to provide expertise in occupational health as it relates to emergency operations. When members undergo medical evaluations with outside private clinicians, the standard specifies that the fire department physician must review and approve the evaluation. Testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act, per its Food and Drug Administration (FDA) prescribing information. The label notes that serum testing is used primarily when abuse is suspected, though levels can remain deceptively normal during synthetic androgen misuse. The National Institute on Drug Abuse (NIDA) points out that detecting anabolic compounds requires specialised anti-doping protocols, not conventional workplace drug screens.
Shift Work and Sleep Disruption Effects on Serum Testosterone
Acute sleep restriction measurably suppresses circulating testosterone concentrations in healthy men, but evidence directly measuring chronic shift-work effects in career firefighters remains sparse. In a 2011 laboratory study published in JAMA, Rachel Leproult and Eve Van Cauter evaluated 10 healthy young men with a mean age of 24.3 years. After establishing baseline sleep profiles averaging roughly 8 hours and 55 minutes, participants underwent 3 nights of 10-hour bedtimes followed by 8 nights of 5-hour sleep restriction.
The Leproult and Van Cauter trial demonstrated that one week of 5-hour sleep restriction lowered daytime testosterone concentrations by 10 to 15 percent, dropping from a rested average of 18.4 nmol/L to 16.5 nmol/L across the morning and afternoon. The evening reduction was larger, dropping from 17.9 nmol/L down to 15.5 nmol/L between 2 PM and 10 PM. This established that sleep restriction exerts an acute suppressive effect on testicular endocrine output.
This laboratory finding carries clear methodological limits. It evaluated 10 young healthy individuals in a controlled university environment rather than active shift workers facing chronic operational exposures over decades. Firefighter-specific field research remains thin. When occupational studies evaluated career firefighters moving from a traditional 24/48 shift schedule to an alternate 1/3/2/3 rotation, researchers measured salivary markers alongside surveys, but published outcomes focused on cortisol levels, quality of life, and perceived sleep quality rather than serum testosterone values. Fatigue on a rotating shift schedule has several documented causes, and the diagnostic guideline below turns on symptoms plus repeated morning measurements rather than on fatigue alone. Our pages on signs of low testosterone and the home sleep apnea test cover what each one measures.
Diagnostic Requirements and Contraindications for Starting Therapy
Clinical guidelines require documented physical symptoms and repeated morning laboratory confirmations before establishing a diagnosis of hypogonadism. The clinical practice guideline from the Endocrine Society, authored by Shalender Bhasin and colleagues using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, recommends against making a diagnosis based on a single measurement. Clinicians must confirm low concentrations by repeating morning fasting total testosterone draws on separate days.
When total testosterone sits near the lower limit of normal, or when an individual has conditions that alter sex hormone-binding globulin (SHBG), the guideline recommends measuring free testosterone through equilibrium dialysis or an accurate calculation formula. Our analysis of free vs total testosterone and comprehensive mens hormone panel testing outlines these specific diagnostic boundaries.
FDA-approved product labeling limits testosterone indications to classical hypogonadism resulting from pituitary or testicular disease. Labels carry an explicit Limitation of Use stating that the safety and efficacy of therapy have not been established for age-related hypogonadism. Furthermore, the Endocrine Society recommends against starting therapy in individuals with an elevated baseline haematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, thrombophilia, or a myocardial infarction (MI) or stroke within the past 6 months.
Cardiovascular Evidence from the TRAVERSE Trial and Regulatory Changes
The largest randomised safety trial of testosterone replacement therapy established non-inferiority for major adverse cardiovascular events while identifying specific vascular and rhythm signals. Published in the New England Journal of Medicine in 2023, the TRAVERSE trial enrolled 5,246 men aged 45 to 80 with pre-existing cardiovascular disease or high risk, clinical hypogonadal symptoms, and two fasting testosterone concentrations below 300 ng/dL.
Participants received daily transdermal 1.62% gel adjusted to maintain testosterone concentrations between 350 and 750 ng/dL, or a matching placebo gel. Over a mean treatment duration of 21.7 months and a mean follow-up of 33.0 months, the primary composite endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke occurred in 182 patients (7.0 percent) in the testosterone group and 190 patients (7.3 percent) in the placebo group. With a hazard ratio of 0.96 and a 95 percent confidence interval of 0.78 to 1.17, testosterone met the pre-specified statistical standard for non-inferiority against placebo.
The trial flagged secondary safety signals that warrant occupational attention. TRAVERSE reported a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism (PE) among participants receiving testosterone. Transdermal gel also increased mean systolic blood pressure by 1.0 mm Hg over 36 months, whereas the placebo group experienced a 0.5 mm Hg reduction, representing a net between-group increase of 1.5 mm Hg. On 28 February 2025, the FDA issued class-wide labeling changes that removed warnings regarding adverse cardiovascular outcomes from the Boxed Warning of all approved products. However, the agency added new warnings regarding blood pressure elevations and venous thromboembolism (VTE). Comprehensive clinical details appear in our overview of TRT side effects and risks.
Occupational Coagulation Strain and Erythrocytosis Risks
Elevated haematocrit from testosterone replacement therapy carries heightened significance in firefighting due to the acute dehydration and procoagulant states induced by structural fire suppression. Testosterone raises red blood cell mass, and the FDA label states that an increase in red blood cell mass may increase the risk of thromboembolic events. In a pooled meta-analysis of 19 randomised trials by Calof et al., treated men were nearly four times as likely to develop a haematocrit above 50 percent compared to placebo (odds ratio 3.69, 95 percent confidence interval 1.82 to 7.51). A systematic review by Fernández-Balsells et al. found an average weighted haematocrit increase of 3.18 percentage points across 51 studies.
Delivery routes alter the likelihood of red cell elevation. Published clinical evidence indicates that approximately 66.7 percent of men receiving short-acting intramuscular injections develop haematocrit levels above 50 percent, compared to 35.1 percent of patients using subcutaneous pellets and 12.8 percent using transdermal gels. Guidance on managing these elevations appears in our guide on high hematocrit on TRT.
The occupational environment of firefighting creates unique vascular strain. Research by Smith et al. demonstrated that just 18 minutes of live-fire suppression activity increased platelet counts, platelet activation, and overall coagulatory potential. Platelet function, partial thromboplastin time and factor VIII still reflected a procoagulatory state even after two hours of post-fire recovery, while plasminogen activator inhibitor-1 (PAI-1) suppression of fibrinolysis remained depressed. Research by Hostler et al. confirmed that consecutive bouts of fire suppression drive core temperatures upward and induce maximal cardiovascular strain.
Whether testosterone-induced erythrocytosis actually causes thrombotic events is contested. A published review concludes that few data support an increased risk of cardiovascular events from testosterone-induced erythrocytosis, and that no randomised or prospective study has observed a direct relationship between the two, while TRAVERSE recorded a higher incidence of pulmonary embolism and the FDA label states that increased red cell mass may increase thromboembolic risk.
| Organization or guideline | Baseline threshold | Action or discontinuation threshold | Monitoring schedule |
|---|---|---|---|
| Endocrine Society (as summarised in the peer-reviewed literature) | Above 50% treated as a relative contraindication to initiating | Above 54% treated as a reason to discontinue | Haematocrit or haemoglobin within 2 to 6 months of initiation |
| Other professional societies (literature range) | Not stated in the summarised range | Action thresholds range from 52% to 55% | Not published in the summarised range |
| FDA drug labeling (Testim prescribing information) | Check hematocrit prior to initiating treatment | No numerical cut-off; stop therapy if hematocrit becomes elevated | Re-evaluate at 3 to 6 months, then annually |
Line-of-Duty Cardiac Mortality and Reporting Discrepancies
Cardiovascular events constitute the single largest category of firefighter line-of-duty deaths, though published percentages fluctuate depending on how agencies define their counting criteria. Provisional fatality records from the United States Fire Administration (USFA) documented 81 on-duty firefighter deaths in 2025. Of those 81 deaths, 48 were caused by stress or overexertion leading to cardiovascular collapse, representing 59 percent of the total. Annual USFA on-duty fatality figures from 2016 through 2025 were 92, 93, 85, 65, 102, 141, 98, 93, 72, and 81.
A separate analytical summary published by the USFA on cardiovascular disease describes sudden cardiac events as accounting for nearly 45 percent of all deaths, identifying operational stress, shift work, and sleep loss as compounding factors. In contrast, annual reporting from the NFPA on fatal firefighter injuries counted 83 fatalities in 2025 using expanded criteria that incorporate deaths occurring within 24 hours of duty. NFPA calculated 27 on-duty heart attacks, representing 42 percent of the 65 traditional on-duty fatalities, along with 18 heart attacks occurring within 24 hours of operational service.
Emergency duties carry disproportionate cardiac danger. In a study in the New England Journal of Medicine, Kales et al. demonstrated that the odds of fatal coronary heart disease (CHD) were 12.1 to 136 times higher during fire suppression than during routine administrative work. Fire suppression accounted for 32.1 percent of all cardiac deaths despite occupying a small fraction of a firefighter's total work hours. An autopsy investigation by Smith et al. of 276 cardiac fatalities revealed that 82 percent possessed comorbid coronary artery disease alongside left ventricular hypertrophy or cardiomegaly, with severe stenosis of 75 percent or greater multiplying mortality odds ninefold.
| Reporting agency and dataset | Total recorded fatalities | Cardiac-related fatalities | Criteria and inclusion parameters |
|---|---|---|---|
| USFA provisional dataset (2025) | 81 line-of-duty deaths | 48 deaths (59%) | Categorized under stress or overexertion causes |
| NFPA standard criteria (2025) | 65 on-duty deaths | 27 deaths (42%) | Restricted to traditional immediate on-duty heart attacks |
| NFPA expanded criteria (2025) | 83 total fatalities | 45 deaths (54%) | Includes 27 on-duty plus 18 deaths within 24 hours of duty |
Physical Readiness Findings and Functional Trial Limits
Clinical trials in older hypogonadal men show measurable gains in muscle mass and isolated strength, but these investigations did not assess job-specific firefighting tasks. In the multicentre Testosterone Trials published by Snyder and colleagues in the New England Journal of Medicine, researchers evaluated 790 men aged 65 and older with serum testosterone below 275 ng/dL. In the specific Physical Function Trial reported by Snyder et al., the primary endpoint failed: the percentage of men who improved their six-minute walking distance by at least 50 metres did not differ significantly between testosterone and placebo.
Statistical significance was reached only after pooling participants across all three component trials, with 20.5 percent of testosterone recipients achieving the 50-metre threshold compared to 12.6 percent of placebo recipients (P=0.003). The authors concluded that raising concentrations from moderately low to mid-normal yielded moderate benefits for sexual function and mild benefits for mood, but no significant improvements in general vitality or walking capacity. A three-year double-blind trial conducted by Storer et al. in men aged 60 and older on 1% gel showed modest gains: loaded stair-climbing power increased by 22.4 watts, chest-press power improved by 22.5 watts, and lean mass rose significantly.
These clinical findings have real limits when applied to emergency services. Both trials examined older, predominantly sedentary populations with age-related hormone decline rather than active tactical operators. Neither study evaluated high-intensity occupational evolutions, heavy gear loads, or breathing apparatus consumption. For realistic expectations on physiological timelines, review our guide on how long does TRT take to work.
The Endocrine Society guideline recommends against starting therapy in men with elevated haematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, thrombophilia, or a myocardial infarction or stroke within the last 6 months. FDA labelling restricts the approved indication to primary and hypogonadotropic hypogonadism, and states that safety and efficacy in age-related hypogonadism have not been established. Our operational assessment would change if future editions of NFPA 1580 introduce an explicit exclusionary medication schedule, or if prospective clinical trials evaluate testosterone therapy specifically within tactical populations under live structural firefighting conditions. Which edition a department enforces is a local question: NIOSH documented a 2025 fatality at a department still operating under a policy that adopted the 2013 edition of NFPA 1582 by reference. The current consolidated standard is NFPA 1580 (2025).
Frequently Asked Questions
Does testosterone therapy disqualify a firefighter?
Testosterone replacement therapy does not automatically disqualify an individual under fire service occupational standards. Standards like NFPA 1580 and the retired NFPA 1582 do not maintain a universal prohibited drug list. Instead, the standards establish a duty to report medical conditions and prescription medications to the fire department physician. That physician determines operational readiness based on whether the underlying condition or treatment impairs the member's ability to safely perform essential emergency operations, rather than issuing a blanket ban on the hormone itself.
Is NFPA 1582 still the current standard?
NFPA 1582 no longer exists as an independent document. It was combined into the consolidated standard NFPA 1580, titled Standard for Emergency Responder Occupational Health and Wellness, alongside standards 1581, 1583, and 1584. The 2025 edition of NFPA 1580 is the current active standard, while the 2022 edition was the final standalone release of NFPA 1582. However, local fire departments frequently adopt standards years behind schedule, meaning many departments still operate under older historical editions.
Do firefighter physicals test for testosterone?
The one career-department evaluation documented in detail by NIOSH comprised urinalysis, vision and hearing tests, a chest x-ray, blood work, a pulmonary function test, an electrocardiogram, a urine or breath alcohol and drug screen, an examination of organ systems, and a respirator fit test. No hormone or endocrine assay appeared on it, and the words testosterone, hormone, endocrine, anabolic and steroid appear zero times across that 21-page report. What any individual department screens for is set by that department, and no authoritative national source publishes a single answer. The National Institute on Drug Abuse describes anabolic-steroid detection as a specialised anti-doping function relying on stored per-athlete reference samples, not a routine workplace test.
Does shift work lower testosterone?
Controlled clinical research indicates that acute sleep restriction suppresses circulating testosterone levels. A laboratory trial demonstrated that limiting healthy men to 5 hours of sleep per night for one week reduced daytime testosterone concentrations by 10 to 15 percent. However, this study evaluated a small cohort of young men in an acute laboratory environment. Long-term studies evaluating career firefighters across standard shift rotations have documented disruptions in sleep quality and cortisol, but evidence confirming permanent clinical hypogonadism from shift work alone remains sparse.
Does TRT improve firefighter physical performance?
Clinical trials have not evaluated whether testosterone replacement therapy enhances performance on actual firefighting tasks. Large randomised controlled trials in older hypogonadal men showed modest increases in lean body mass, stair-climbing power, and chest-press strength. However, the Physical Function Trial of the Testosterone Trials missed its primary endpoint for walking distance improvements. No published clinical studies have assessed whether hormone therapy improves occupational capabilities such as hose advancement, victim extraction, or fireground endurance.
Why does hematocrit matter more for firefighters?
Testosterone stimulates erythropoiesis, raising haematocrit and thickening circulating blood. In firefighting, this red cell elevation interacts with severe operational heat stress, heavy gear, and rapid sweat-induced dehydration. Controlled fireground studies demonstrate that live-fire suppression induces an immediate procoagulant state with heightened platelet activation and depressed clot breakdown. When elevated baseline red cell volume meets acute thermal dehydration and platelet activation, cardiovascular strain multiplies during peak emergency operations.
What share of firefighter line-of-duty deaths are cardiac?
Published cardiac mortality proportions range from roughly 40 to 60 percent depending on agency counting criteria. Provisional USFA figures for 2025 attributed 48 of 81 line-of-duty deaths (59 percent) to stress or overexertion leading to cardiovascular collapse. NFPA reported that heart attacks caused 42 percent of traditional on-duty fatalities in 2025, but that proportion rises when counting deaths that occur within 24 hours of duty. Research confirms that the odds of fatal cardiac events are significantly higher during fire suppression than non-emergency duties.
Do I have to report a testosterone prescription to my department?
Under occupational standards such as NFPA 1580, firefighters have an explicit duty to report medical conditions and medications that could affect their ability to perform essential job tasks safely. Fire department medical policies routinely mandate that personnel disclose all prescription and non-prescription drug use to the fire department physician. Because testosterone therapy requires ongoing clinical monitoring for haematocrit, blood pressure, and cardiovascular stability, failure to report a controlled prescription violates standard occupational compliance policies.